


His ADHD symptoms can be disruptive, but there's a great kid in there.<sup>1,2</sup>  
Now there's a new way to help him out



**NEW!**  
for the  
treatment  
of ADHD<sup>3</sup>

**intuniv**<sup>TM</sup>  
(guanfacine) Extended  
Release Tablets  
1mg, 2mg, 3mg, 4mg

A new way to reach the kid within

### Important Safety Information

INTUNIV is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17. Efficacy was established in two controlled clinical trials (8 and 9 weeks in duration). The physician electing to use INTUNIV for extended periods should periodically reevaluate its long-term usefulness for the individual patient.

INTUNIV should not be used in patients with a history of hypersensitivity to guanfacine or any of its inactive ingredients or by patients taking other products containing guanfacine.

Hypotension, bradycardia, and syncope were observed in clinical trials. Use INTUNIV with caution in treating patients who have experienced hypotension, bradycardia, heart block, or syncope, or who may have a condition that predisposes them to syncope; are treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope. Heart rate and blood pressure should be measured prior to initiation of therapy, following dose increases, and periodically while on therapy. Patients should be advised to avoid becoming dehydrated or overheated.

Sedation and somnolence were commonly observed in clinical trials. The potential for additive sedative effects with CNS depressant drugs should be considered. Patients should be cautioned against operating heavy equipment or driving until they know how they respond to INTUNIV. Avoid use with alcohol.

Common adverse reactions in patients taking INTUNIV that may be dose related over the range of 1 to 4 mg/day include somnolence, sedation, abdominal pain, dizziness, hypotension/decreased blood pressure, dry mouth, and constipation.

**Please see Brief Summary of Full Prescribing Information on adjacent page.**

**References:** 1. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000. 2. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*. 2007;46(7):894-921. 3. Intuniv [package insert]. Wayne, PA: Shire US Inc; 08/2009.

**Shire**

INTUNIV is a trademark of Shire LLC.  
1-800-828-2088 www.intuniv.com  
©2009 Shire US Inc., Wayne, PA 19087 INT-00154 09/09

Learn more at [www.intuniv.com](http://www.intuniv.com)